A novel immunoadsorbent for rheumatoid arthritis therapy--preparation and efficacy evaluation.
OBJECTIVE
To develop a novel immunoadsorbent for rheumatoid arthritis (RA) therapy.


METHODS
A RA immunoadsorbent was developed by binding heat-aggregated human IgG(HAHIgG) to porous agar gel beads. Its adsorption capacity for rheumatoid factors (RFs), storage stability and blood compatibility were evaluated.


RESULTS
The coupling yield of HAHIgG on the carrier was 6.0 mg/g wet gel. Saturation adsorption capacity of the adsorbent for IgMRF, IgGRF and IgARF were 3400, 2240 and 2400 IU/g, respectively. The adsorbent can be stored at 4 degrees C for three months without significant variance in its activity. Its fine permeability and hemocompatibility were demonstrated by extracorporeal hemoperfusion on rabbits.


CONCLUSIONS
HAHIgG/agar gel is a safe and effective immunoadsorbent for RA therapy, its potential clinical use is promising in the future.
Fu
C
C
Institute for Molecular Biology, Bioactive Material Research Laboratory, Nankai University, PR China.
Yu
Y
Y
Chen
C
C
D000362:Agar; D000818:Animals; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D004356:Drug Storage; D006464:Hemoperfusion; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D007163:Immunosorbent Techniques; D007164:Immunosorbents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D011485:Protein Binding; D011817:Rabbits; D012217:Rheumatoid Factor / Q000097:blood / Q000378:metabolism
D007074:Immunoglobulin G; D007164:Immunosorbents; D000362:Agar; D012217:Rheumatoid Factor